secwatch.observer — SEC 8-K summary
======================================

Issuer:     Immunome Inc. (IMNM)
CIK:        0001472012
Form:       8-K
Filed at:   2023-05-05T23:59:59+00:00
Accession:  0001104659-23-056320
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Immunome reports Q1 2023 net loss of $4.3M; posts $2.4M collaboration revenue from AbbVie deal
--------------------------------------------------------------------------------

- Collaboration revenue of $2.4M from AbbVie strategic deal for up to 10 novel antibody-target pairs.
- Net loss of $4.3M for Q1 2023; R&D expenses $3.9M, G&A expenses $2.8M.
- Cash and cash equivalents $44.4M as of March 31, 2023.
- AbbVie deal includes $30M upfront, $70M platform milestones, and up to $120M per target in development/commercial milestones.
- Formed Antibody-Drug Conjugate and T Cell Redirection Advisory Board in February 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1472012/000110465923056320/0001104659-23-056320-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1472012/000110465923056320/tm2314520d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-056320

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer